As of June 3, a total of 723 million new coronavirus vaccines have been reported in 31 provinces, autonomous regions, municipalities directly under the central government and Xinjiang production and Construction Corps. On June 1 local time, who announced that China's Kexing Xinguan vaccine would be included in the "emergency use list". When can people aged 3-18 be vaccinated? How to speed up vaccination? In this issue of "news 1 + 1", Mr. Bai Yansong is paying close attention to Yin Weidong, chairman of Kexing holding Biotechnology Co., Ltd.

Kexing vaccine officially passed who certification for emergency use

Yin Weidong, chairman of Kexing holding Biotechnology Co., Ltd.: Kexing Zhongwei has entered the WHO emergency use list, which is the 47th emergency use. Before that, Kexing has obtained emergency use in 46 countries outside China. This means meeting the production quality standards of more countries and providing vaccines to more countries. Many countries do not have the basis and conditions for vaccine review, so they will accept the certification of who and then purchase; What's more important is that some international organizations, such as covax global new crown vaccine program, purchase vaccines through such demonstration, which means to provide vaccines to more countries in a wider range.

Kexing vaccine is ready to provide vaccines to more countries in terms of production preparation and capacity improvement

Yin Weidong, chairman of Kexing holding Biotechnology Co., Ltd.: when designing vaccine production capacity, China's needs and global needs have been taken into account. At present, the design capacity of Kexing Zhongwei is 2 billion yuan per year. However, according to the situation in the first half of this year, the production capacity has exceeded the design capacity. We have now provided more than 600 million doses of vaccines to the world, which means that we have the conditions to further improve the quality standards, production preparation and production capacity of vaccines to who and more countries.

The state has approved the age range of emergency use of Kexing Xinguan vaccine to be extended to more than 3 years old

Yin Weidong, chairman of Kexing holding Biotechnology Co., Ltd.: Kexing Zhongwei has a clinical study on minors, which was started at the beginning of this year. At present, it has completed phase I and phase II clinical studies. Clinical studies of hundreds of people show that after vaccination in children group (3-17 years old), its safety is good, which is the same as that in adults group (18 years old). At the same time, antibody levels are the same as in adults. The data on safety and effectiveness have been reported to the joint prevention and control mechanism and the State Food and drug administration. We have submitted an application for the emergency use of the vaccine. Now the state has approved the age range of emergency use of Kexing Xinguan vaccine to be extended to over 3 years old. However, when the vaccine will be used in the lower age group will be organized by the National Health Commission, According to China's current epidemic needs and population composition, we will promote the use of vaccines in different age groups in an orderly manner.

It is safe and effective for the elderly after vaccination

Yin Weidong, chairman of Kexing holding Biotechnology Co., Ltd.: in the phase III clinical study, the elderly group over 60 years old has been involved, but when Kexing vaccine is applied in the real world, especially in Chile, Brazil and Turkey, where the epidemic situation is more serious, their immunization strategy starts from the high age and starts from the age of 100, So now we have large-scale real-world data. At present, the data obtained in Chile and Brazil, in fact, mainly consist of the elderly, which has fully shown that the safety of vaccination for the elderly is very reliable, and the protection effect is also very good.

The acceleration of vaccination has these four factors

Yin Weidong, chairman of Kexing holding Biotechnology Co., Ltd.: ① the safety of vaccines, with the public vaccination, more and more safe vaccines will greatly increase the vaccination rate; ② In the process of vaccination, the effect of the vaccine has also become the public's willingness to vaccinate. Recently, the real-world data reported in Brazil, Indonesia and Chile greatly promoted the public's vaccination; ③ According to the survey in Zhejiang and other places, the public's willingness to vaccinate is very high, but sometimes the supply speed is not enough. Now we have increased the monthly supply to several hundred million doses, which can ensure that the public can get the vaccine in time when they are willing to vaccinate; ④ The government is very effective in organizing medical staff to work overtime, even day and night to meet the wishes of the public. These four elements can ensure the rapid immunization of the population.

Mass vaccination in China is expected to exceed 1 billion doses by the end of June

Yin Weidong, chairman of Kexing holding Biotechnology Co., Ltd.: it is a very complicated process to organize such a large-scale vaccination in China. As a major vaccine supplier, Kexing has adjusted the quantity of vaccine supply since this year, mainly domestic supply, because there is a very important situation in China, that is, most people are in the immunization gap. Therefore, we provide vaccines on a large scale to quickly complete domestic vaccination. Judging from the current situation, at the end of June, we are very confident that by providing vaccines, 560 million people in our country can be protected, that is, more than 1 billion doses can be vaccinated.